Investors & Media

WATERTOWN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers  The OncoSignature® test will run on Akoya’s PhenoImager™ Solution

WATERTOWN, Massachusetts, June 22, 2022 – Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary proteomics-based technologies driving a new era of precision medicine,

WATERTOWN, Massachusetts,   April 20, 2022  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced the appointments of Rasmus Holm-Jorgensen as the company’s chief financial officer,

WATERTOWN, Massachusetts, March 16, 2022  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced that Peter Blume-Jensen, M.D., Ph.D., Acrivon’s chief executive officer and founder,

WATERTOWN, Massachusetts,   December 8, 2021  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary, proteomics-based technologies driving a new era of precision-based medicine, today announced the establishment of its scientific advisory board.

WATERTOWN, Massachusetts,   November 29, 2021  –  Acrivon Therapeutics, Inc ., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced that Peter Blume-Jensen, M.D., Ph.D., Acrivon’s chief executive officer and

WATERTOWN, Massachusetts, November 11, 2021 – Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based medicine, today announced the successful completion of an oversubscribed $100 million Series B financing.

WATERTOWN, Massachusetts, June 29, 2021 – Acrivon Therapeutics, Inc., a clinical-stage precision oncology therapeutics company with a unique patient selection platform, today announced its launch with multiple key catalysts,